Petros Pharmaceuticals, Inc. PTPI NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

13/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Petros Pharmaceuticals, Inc. (PTPI) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2,768.29%, forward earnings yield 5,000.00%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E 0.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -2,768.29%).
Forward P/E 0.0 — analysts expect a return to profitability with estimated EPS of $0.34 for FY2028.
Trailing Earnings Yield -2,768.29% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 5,000.00% as earnings recover.

Overall SharesGrow Score: 12/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

13/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

41/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — PTPI

Valuation Multiples

P/E (TTM)0.0

Forward P/E0.0

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.08

P/S Ratio0.26

EV/EBITDA0.5

Per Share Data

EPS (TTM)$-0.17

Forward EPS (Est.)$0.34

Book Value / Share$0.08

Revenue / Share$0.02

FCF / Share$-0.11

Yields & Fair Value

Earnings Yield-2,768.29%

Forward Earnings Yield5,000.00%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2018	-3.1	0.00	-59.33	7.10	-
2019	-7.5	0.13	30.60	15.75	-
2020	-28.5	0.40	33.63	61.45	-
2021	-100.9	1.28	25.50	116.06	-
2022	-6.0	-0.35	7.22	20.12	-
2023	-5.6	0.16	3.63	7.78	-
2024	-5.5	0.12	-10.59	15.46	1,635.43%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2018	$-324.73	$14.05M	$-32.47M	-231.1%
2019	$-132.16	$15.58M	$-32.51M	-208.7%
2020	$-38.55	$9.56M	$-20.59M	-215.3%
2021	$-8.25	$7.81M	$-9.36M	-119.8%
2022	$-9.68	$5.99M	$-20.04M	-334.4%
2023	$-6.35	$5.82M	$-8.16M	-140.2%
2024	$-0.02	$5.11M	$-14.32M	-280.1%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-27.50	$-27.50 – $-27.50	$11.03M	$11.03M – $11.03M	1
2027	$-17.50	$-17.50 – $-17.50	$20.63M	$20.63M – $20.63M	1
2028	$0.34	$0.34 – $0.34	$27.78M	$27.78M – $27.78M	1